"The ability for Biobanks to embrace the changing perspective of viewing the biospecimen as a potential work product and provide focus on the life cycle and related process chain and related pipeline planning will be hugely beneficial."
"Towards this pathway a few key things will be incredibly important in fostering success: voluntary adaptation related to necessary cultural changes to further cement and centralize appropriate infrastructure either in instituting center of excellence/biological resource center, core facility and/or integrated Biobank network models (in conjunction with tools to aide interoperability, formal induction and evolution towards best in tandem with integration of evidence based practice preparation) and Biobusiness activities (i.e. cost recovery implementation and fit for purpose resource organization and resource evaluation)."
5 "Post implementation, these key steps will then contribute to foster viability as well as long term sustainability while providing equitable return on investment.
The collaborative theory will then be put to the test as Biobanks transition from their current pre-competitive to the future competitive yet potentially collaborative environment. It will therefore be essential to demonstrate the "value add" of utilizing network tools, strategic alliances and private-public partnerships through proof of concepts pilots that offer shared equity and methodologies to categorize and aggregate sample collections, enhance overall quality of biospecimens and associated data and expedite collaboration aimed at discoveries which will ensure real time practice of molecular and personalized medicine such as those related to biomarker validation."
6 "It will also be crucially important to disseminate experiential lessons learned and scientific data amongst scientific and professional trans-boundary disciplines to create a fully operational evidence based environment. This ability to achieve a trans-boundary educational, yet functional environment will succeed in reducing lags, roadblocks and related impediments that currently exist and may naturally occur along this pathway. In accordance with evolving biospecimen science, an additional challenge will be quantifying current "catch phrases" i.e. specimen integrity and benchmark specimens and quality marker reference ranges. Ideally these should then all be implemented back into the process chain and biospecimen lifecycle management process... 
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